S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:ANNX

Annexon Stock Forecast, Price & News

$31.01
+2.00 (+6.89 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.01
Now: $31.01
$31.93
50-Day Range
$22.00
MA: $27.03
$33.04
52-Week Range
$15.33
Now: $31.01
$38.01
Volume214,777 shs
Average Volume140,809 shs
Market Capitalization$1.18 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
Annexon logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANNX
CUSIPN/A
CIKN/A
Phone650 822 5500
Employees38
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-37,180,000.00

Miscellaneous

Market Cap$1.18 billion
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

206th out of 1,972 stocks

Pharmaceutical Preparations Industry

94th out of 772 stocks

Analyst Opinion: 2.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$31.01
+2.00 (+6.89 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Annexon (NASDAQ:ANNX) Frequently Asked Questions

Is Annexon a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Annexon stock.
View analyst ratings for Annexon
or view top-rated stocks.

What stocks does MarketBeat like better than Annexon?

Wall Street analysts have given Annexon a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Annexon wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Annexon's next earnings date?

Annexon is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Annexon
.

How were Annexon's earnings last quarter?

Annexon, Inc. (NASDAQ:ANNX) announced its quarterly earnings data on Sunday, November, 15th. The company reported ($0.55) EPS for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.20.
View Annexon's earnings history
.

What price target have analysts set for ANNX?

5 equities research analysts have issued 12-month target prices for Annexon's shares. Their forecasts range from $33.00 to $37.00. On average, they anticipate Annexon's share price to reach $34.33 in the next year. This suggests a possible upside of 10.7% from the stock's current price.
View analysts' price targets for Annexon
or view top-rated stocks among Wall Street analysts.

Who are Annexon's key executives?

Annexon's management team includes the following people:
  • Mr. Douglas Love J.D., Esq., CEO, Pres & Director (Age 54, Pay $546.67k)
  • Ms. Jennifer Lew, Exec. VP & CFO (Age 48, Pay $423.03k)
  • Dr. Sanjay Keswani B.Sc., MBBS, Exec. VP & Chief Medical Officer (Age 51, Pay $546.01k)
  • Dr. Arnon Rosenthal, Founder (Age 65)
  • Dr. Ted Yednock Ph.D., Exec. VP & Chief Scientific Officer (Age 63)
  • Miriam Mason, Sr. VP of Corp. Communications
  • Mr. Michael Overdorf, Exec. VP & Chief Bus. Officer (Age 51)
  • Mirella Villa Del Toro, Sec.

Who are some of Annexon's key competitors?

What other stocks do shareholders of Annexon own?

When did Annexon IPO?

(ANNX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO.

What is Annexon's stock symbol?

Annexon trades on the NASDAQ under the ticker symbol "ANNX."

When did Annexon's lock-up period expire?

Annexon's lock-up period expired on Wednesday, January 20th. Annexon had issued 14,750,000 shares in its public offering on July 24th. The total size of the offering was $250,750,000 based on an initial share price of $17.00. Since the expiration of Annexon's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Annexon's major shareholders?

Annexon's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.52%), Satter Management CO. L.P. (5.12%), Federated Hermes Inc. (3.77%), Price T Rowe Associates Inc. MD (3.16%), Alliancebernstein L.P. (2.98%) and Janus Henderson Group PLC (2.43%). Company insiders that own Annexon stock include Bain Capital Life Sciences Fun, James E Flynn, Jennifer Lew and Muneer A Satter.
View institutional ownership trends for Annexon
.

Which institutional investors are selling Annexon stock?

ANNX stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., and Acuta Capital Partners LLC.
View insider buying and selling activity for Annexon
or view top insider-selling stocks.

Which institutional investors are buying Annexon stock?

ANNX stock was bought by a variety of institutional investors in the last quarter, including Satter Management CO. L.P., Price T Rowe Associates Inc. MD, Alliancebernstein L.P., Rhenman & Partners Asset Management AB, Federated Hermes Inc., Alyeska Investment Group L.P., Alyeska Investment Group L.P., and Avidity Partners Management LP. Company insiders that have bought Annexon stock in the last two years include Bain Capital Life Sciences Fun, James E Flynn, Jennifer Lew, and Muneer A Satter.
View insider buying and selling activity for Annexon
or or view top insider-buying stocks.

How do I buy shares of Annexon?

Shares of ANNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Annexon's stock price today?

One share of ANNX stock can currently be purchased for approximately $31.01.

How much money does Annexon make?

Annexon has a market capitalization of $1.18 billion.

How many employees does Annexon have?

Annexon employs 38 workers across the globe.

What is Annexon's official website?

The official website for Annexon is www.annexonbio.com.

How can I contact Annexon?

The company can be reached via phone at 650 822 5500 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.